Objective To evaluate the efficacy of treatment options for patients with recurrent ovarian cancer.Methods From 1990 to 2000, 54 patients with recurrent ovarian cancer primarily treated in Peking Union Medical College Hospital were selected and reviewed.All the clinical data related to the recurrent tumor were collected.Two-side P values for differences in survival were calculated by the Cox regression model.Results The platinum-free interval >6 months and the surgery followed by salvage chemotherapy prolonged survival time of the patients with recurrent ovarian cancer (95% CI=0.153-0.987, P=0.047; 95% CI=1.611-10.914, P=0.003, respectively).The increased number of chemotherapy cycles (> 10 months) offered some benefit on the survival (95% CI=0.110-1.090, P=0.070).The initiation of treatment and chemotherapy regiments failed to demonstrate an improvement in survival.Conclusion The treatment options for patients with recurrent ovarian cancer depend on the platinum-free-interval of the patients.A strategy of secondary surgical cytoreduction followed by salvage chemotherapy is suggested for the patients with platinum-sensitive disease. Objective To evaluate the efficacy of treatment options for patients with recurrent ovarian cancer. Methods From 1990 to 2000, 54 patients with recurrent ovarian cancer predosed in Peking Union Medical College Hospital were selected and reviewed. All of the clinical data related to the recurrent tumor were Results. The platinum-free interval> 6 months and the surgery followed by salvage chemotherapy prolonged survival time of the patients with recurrent ovarian cancer (95% CI = 95% CI = 1.611-10.914, P = 0.003, respectively). The increased number of cycles (> 10 months) offered some benefit on the survival (95% CI = 0.110-1.090, P = 0.070). Initiation of treatment and chemotherapy regiments failed to demonstrate an improvement in survival. Confluence The treatment options for patients with recurrent ovarian cancer depend on the platinum-free-interval of the p atients. A strategy of secondary surgical cytoreduction followed by salvage chemotherapy is suggested for the patients with platinum-sensitive disease.